Trial Profile
A randomized, double-blinded, controlled, Phase I clinical trial to assess the safety, tolerability and immunogenicity of NBP607 (Trivalent Inactivated Cell-Culture Influenza Vaccine) compared to egg-based influenza vaccine in healthy adult volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs NBP 607 (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors SK Chemicals
- 03 Feb 2015 New trial record